Day: April 17, 2023

Mobivity Enhances Connected Rewards Solution with Zero-Cost Media Offering for Restaurant Brands

Written by Customer Service on April 17, 2023. Posted in Public Companies.

New Customer Acquisition Mobile Game Offering Debuts at Restaurant Leadership Conference PHOENIX, April 17, 2023 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB: MFON), a global provider of personalized reward solutions that drive customer acquisition, frequency, and spend, announced today a new zero-cost media offering for its cloud-based Connected Rewards Marketplace. The Connected Rewards Marketplace connects restaurants and other major brands to game developers enabling them to reach new audiences more affordably while simultaneously offering restaurant and brand rewards to mobile gamers. Mobivity is debuting the new offering at the Restaurant Leadership Conference in Phoenix this week. As both restaurant brands and game developers are facing increased budget pressure with rising competition and costs for limited audience...

Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events

Written by Customer Service on April 17, 2023. Posted in Public Companies.

Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 BOSTON, April 17, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the following upcoming ulixacaltamide presentations and events focused on Essential Tremor (ET): Medical Conference Presentations75th Annual American Academy of Neurology (AAN), Boston, MASummary: Industry talk presenting Essential1 topline results Title: Ulixacaltamide Essential1 ET Topline Results Date/Time: Sunday, April 23, 2023 at 1:00 p.m. EDT (Emerging Neurologic Care Presentation Stage in the Exhibit Hall)World Congress...

GREYSTONE LOGISTICS, INC. REPORTS RESULTS OF OPERATIONS FOR THE NINE MONTHS AND THREE MONTHS ENDED FEBRUARY 28, 2023

Written by Customer Service on April 17, 2023. Posted in Public Companies.

Tulsa, OK, April 17, 2023 (GLOBE NEWSWIRE) — (OTCQB:GLGI). Tulsa-based Greystone Logistics, Inc. reports results of operations for the nine and three months ended February 28, 2023. Greystone recorded net income available to common stockholders (net income less preferred dividends and income from non-controlling interests) for the nine months ended February 28, 2023, of $4,471,124, or $0.16 per share, compared to $3,044,535, or $0.11 per share, for the prior nine months. Net income was $4,881,990 and $3,496,217 for the nine months ended February 28, 2023 and 2022, respectively. EBITDA for the nine months ended February 28, 2023, was $10,109,572 compared to $8,237,357 for the nine months ended February 28, 2022. Operations for the three months ended February 28, 2023, resulted in net income to common stockholders (net income less...

Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent

Written by Customer Service on April 17, 2023. Posted in Public Companies.

Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa., April 17, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the European Patent Office has granted Patent No. 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates. Windtree has preclinical drug candidates with dual mechanisms of action (inhibition of the Na+/K+ pump and activation of SERCA2a) as well as pure SERCA2a activators (devoid of action on the Na+/K+ pump). The new patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection until July 2038 for the...

PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting

Written by Customer Service on April 17, 2023. Posted in Public Companies.

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts. Oral Presentation: Title: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Myotonic Dystrophy Type 1 (DM1)Program Number: S48.001Session Topic: Therapeutics for Muscle Disease Date & Time: Thursday, April 27, 2023 at 3:30pm ETPresenter: Ashling Holland, Ph.D., Director of Preclinical Development Poster Presentation: Title: Preclinical Data Supporting...

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Written by Customer Service on April 17, 2023. Posted in Public Companies.

VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across several tumor types at the 2023 American Association for Cancer Research (AACR) Annual Meeting. VIP236 is a first-in-class SMDC with a tailored design to efficiently treat patients with aggressive and metastatic cancer. VIP236 binds to activated αVβ3 integrin, allowing specific homing to the...

Global Crossing Airlines Continues Triple Digit Year over Year Growth for Key Non-Financial Operating Metrics and Confirms Earning Release Date

Written by Customer Service on April 17, 2023. Posted in Earnings Releases And Operating Results.

MIAMI, April 17, 2023 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (JET: NEO; JET.B: NEO; JETMF: OTCQB) (the “Company” or “GlobalX”) is pleased to provide an update to three key non-financial operating metrics providing increased transparency and timely information to its shareholder base. “GlobalX operated a record 3,134 number of revenue block hours for 40 different customers in Q1 2023 versus 2,470 in Q4 2022, a 27% increase. This is despite losing 75 aircraft days to regularly scheduled maintenance checks and landing gear swaps. In addition, we grew our pilot headcount by 41% since December 2022, investing in a strong pipeline of pilots in advance of our planned aircraft deliveries,” said Ed Wegel, Chairman and CEO. A table of key non-financial operating metrics is set forth below:BLH Net AC Days Pilot PoolMonth-Year BLH...

electroCore Provides Select First Quarter 2023 Financial Guidance

Written by Customer Service on April 17, 2023. Posted in Earnings Releases And Operating Results.

Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46% increase over first quarter of 2022 Revenue in first full quarter of Truvaga sales of approximately $147,000 expectedROCKAWAY, N.J., April 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary unaudited financial guidance for the first quarter of 2023. Financial GuidancePreliminary unaudited financial guidance for the first quarter of 2023: Revenue: The Company anticipates reporting record quarterly revenue of approximately $2.8 million for the quarter ended March 31, 2023. This would represent approximately 46% growth over first quarter 2022 revenue of approximately $1.9 million. Government Channels: For the first...

Welltec Q1 2023 Interim Report and Investor Conference Call Announcement

Written by Customer Service on April 17, 2023. Posted in Earnings Releases And Operating Results.

Q1 2023 Interim Report and Investor Conference Call Announcement Welltec® will disclose its Q1 2023 Interim Report and will discuss the results during an investor conference call to be held Tuesday, May 16th, 2023, at 5 pm CEST. The conference call will be available only to current and prospective bond holders, broker dealers, and securities analysts, and can be accessed by dialing in a few minutes before the start and informing the operator that you would like to participate in Welltec’s investor conference call. Relevant dial-in details and conference ID can be obtained by contacting Mads Brixtofte Rasmussen mbrasmussen@welltec.com and registering for the call. Registration will not be possible once the investor conference has started. The Q1 2023 Interim Report will be made available in the “Investor Room” on Welltec’s website at http://www.welltec.com/investors. For...

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Written by Customer Service on April 17, 2023. Posted in Public Companies.

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, and Alex Fotopoulos, chief technical officer, will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 3:30 p.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event. About Passage Bio Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to provide life-transforming...

Day: April 17, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice